Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nuvo Pharmaceuticals Inc NRIFF


Primary Symbol: MRVFF

Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Bullboard Posts
Comment by HippygirL74on Feb 12, 2010 12:48pm
410 Views
Post# 16780759

RE: RE: RE: Why such a focus

RE: RE: RE: Why such a focusdaydream1, the goal is to find an advantage over Voltaren Gel.  If the animal studies pan out the market is opened up more.  Even if patent protection ends, it would still take years for another product to reach the market, by which time, Pennsaid Plus should be available. A product doesn't have to be first to market to be successful, we might do quite well. i'm sure Covidien will be doing whatever is possible to get Pennsaid Plus with the labelling they desire with the data required to give it a big advantage over Volteren Gel.
As for your comment on Greece? Well the target is America and not Greece.  People are getting older, and will develop chronic illnesses like OA with increasing numbers.  This is a pure growth market.  And NRI does not need to raise money for a long long time, so no matter what happens to the global economy, NRI will still be around.  
Would you sell at
.15 when you have about
.11 in cash.  i would be buying if we ever got that low and i'm sure a lot of smart people would be doing the same.  Got to stay long imo.  EARTH.
Bullboard Posts